Alexandria Real Estate Equities, Inc. (ARE) is a specialized real estate investment trust (REIT) focused on the life sciences industry, with a portfolio centered around research-driven innovation hubs across the United States. Founded in 1994, the company played a major role in establishing the life science real estate niche and has since built a large presence in key biotechnology and research markets, including Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City.
The company develops and operates large-scale collaborative campuses designed to serve biotechnology, pharmaceutical, and scientific research tenants. But despite its established position in the life sciences real estate market, Alexandria Real Estate has struggled to gain traction on Wall Street. The company, currently valued at roughly $8.43 billion by market capitalization, has seen its shares tumble about 29.5% over the past year, sharply underperforming the broader S&P 500 Index ($SPX), which rallied 28% during the same period.
